Replies to post #149680 on Biotech Values

[DonShimoda]

THLD - TH-302 data was presented at ESMO which showed a statsig 6mo PFS vs 3.6mo for gemcitabine alone, however the toxicities, especially at the 340mg level, are going to prove problematic.
http://biotechstrategyblog.com/2012/09/esmo-2012-th-302-pancreatic-cancer-survival-data-fails-to-impress.html/
Also, nice blurb at the end re: abraxane/CELGZ